Amplify Treatments, Testing and Advancements ETF
GERM
GERM was delisted on the 5th of September, 2024.
11 hedge funds and large institutions have $1.43M invested in Amplify Treatments, Testing and Advancements ETF in 2024 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 1 closing their positions.
25% more capital invested
Capital invested by funds: $1.14M → $1.43M (+$289K)
0% more funds holding
Funds holding: 11 → 11 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$222K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$98.5K |
| 3 |
PCMC
Planning Capital Management Corporation
Paoli,
Pennsylvania
|
+$18 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$9.16K |
| 2 |
IA
IFP Advisors
Tampa,
Florida
|
-$3.66K |
| 3 |
CHC
City Holding Co
Charleston,
West Virginia
|
-$3.02K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
-$2.1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $850K | +$98.5K | +5,382 | +13% |
|
|
2
Citadel Advisors
Miami,
Florida
| $515K | +$222K | +12,114 | +75% |
|
|
FDCDDQ
3
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| $27.3K | – | – | – |
|
|
4
UBS Group
Zurich,
Switzerland
| $8.87K | -$9.16K | -501 | -51% |
|
5
Bank of Montreal
Toronto,
Ontario, Canada
| $6K | – | – | – |
|
|
6
Osaic Holdings
Scottsdale,
Arizona
| $5.08K | -$2.1K | -115 | -29% |
|
|
CHC
7
City Holding Co
Charleston,
West Virginia
| $4.28K | -$3.02K | -165 | -41% |
|
|
TAM
8
Tucker Asset Management
Littleton,
Colorado
| $4.21K | – | – | – |
|
|
IA
9
IFP Advisors
Tampa,
Florida
| $3.64K | -$3.66K | -200 | -50% |
|
|
SPIA
10
Steward Partners Investment Advisory
New York
| $2.91K | – | – | – |
|
|
PCMC
11
Planning Capital Management Corporation
Paoli,
Pennsylvania
| $19 | +$18 | +1 | New |
|
GERM Hedge Fund Activity: Q2 2024 in Review
11 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Amplify Treatments, Testing and Advancements ETF (GERM) for Q2 2024, worth a combined $1.43M — up 25% from $1.14M a quarter earlier.
Fund positioning in GERM was balanced in Q2 2024: 1 fund opened new positions, 1 closed out, 2 added to existing stakes and 4 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $222K. The largest seller was UBS Group, cutting an estimated $9.16K.
- 11 institutional investors held Amplify Treatments, Testing and Advancements ETF (GERM) as of Q2 2024, unchanged from Q1 2024.
- Funds reported $1.43M of Amplify Treatments, Testing and Advancements ETF stock for Q2 2024, up 25% quarter-over-quarter.
- 1 fund opened new Amplify Treatments, Testing and Advancements ETF positions in Q2 2024 and 1 closed out, a net change of 0 holders.
- The largest Amplify Treatments, Testing and Advancements ETF buyer in Q2 2024 was Citadel Advisors, an estimated $222K added.
- The largest Amplify Treatments, Testing and Advancements ETF seller in Q2 2024 was UBS Group, an estimated $9.16K sold.
Based on aggregated 13F filings for Q2 2024.